What role do ACE inhibitors or ARBs play in managing IgA nephropathy?

ACE inhibitors (Angiotensin-Converting Enzyme inhibitors) and ARBs (Angiotensin II Receptor Blockers) play a significant role in the management of IgA nephropathy, particularly in terms of protecting kidney function and minimizing glomerular injury as the disease progresses.

In IgA nephropathy, a common cause of kidney disease characterized by the deposition of IgA antibodies in the glomeruli (the filtering units of the kidneys), patients often experience high blood pressure and proteinuria (excess protein in the urine). ACE inhibitors and ARBs help to regulate blood pressure and reduce proteinuria by blocking the effects of angiotensin II, a hormone that can constrict blood vessels and promote kidney damage.

By lowering blood pressure and reducing the workload on the kidneys, these medications can slow the progression of kidney disease, providing a protective effect against further glomerular injury. Additionally, the reduction in proteinuria itself is advantageous, as high levels of protein in the urine can signal worsening kidney function and increased risk for progression to end-stage kidney disease.

Therefore, the use of ACE inhibitors or ARBs in patients with IgA nephropathy is beneficial not only for blood pressure control but also for preserving renal function by mitigating glomerular